Autonomix medical, inc. announces release of the next ceo corner segment

The woodlands, tx, oct. 02, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next ceo corner segment has been published on the company's website. for the ceo corner segment, brad hauser, ceo of autonomix, discusses the company's recently announced longer-term post hoc analysis from its first-in-human proof-of-concept study (“poc 1”) and recent progress made towards the start of u.s. clinical trials, on track to begin in 2026.
AMIX Ratings Summary
AMIX Quant Ranking